MedPath

Vestibular Function Using Mitochondrial Antioxidant Therapy

Early Phase 1
Withdrawn
Conditions
Vestibular Function Disorder
Interventions
Drug: Alpha Lipoic Acid 300mg
Drug: Coenzyme Q10 200mg
Registration Number
NCT05945160
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Brief Summary

To determine if supplementation with known mitochondrial antioxidants (alpha lipoic acid (ALA) and CoQ-10) will stabilize or improve vestibular function in older adults.

Detailed Description

The subjects will be divided into two groups, half will be given daily supplementation with ALA and CoQ-10. The second group will only receive standard of care treatment, with no study drug intervention.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  1. Community dwelling non-gender specific aged 65-90 years of age
  2. For female subjects, confirm that they are post-menopausal
  3. Diagnosed with vestibular dysfunction
  4. Able to provide informed consent
  5. Prepared to adhere to study drug regimen and attend all study visits
Exclusion Criteria
  1. Unable to provide informed consent
  2. Allergy/sensitivity to the study drugs or any of their ingredients
  3. Unable to adhere to study drug regimen or to attend study visits.
  4. Current or past participation within a specified timeframe in another clinical trial, as warranted by the administration of this intervention.
  5. Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  6. Anticoagulant drugs: Anisindione (Miradon), dicumarol and warfarin (Coumadin and Jantoven)
  7. Participants who are currently undergoing treatment with Insulin, Levothyroxine or chemotherapy drugs.
  8. Participants who are undergoing treatment with theophylline.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Nutritional Supplements GroupCoenzyme Q10 200mgAlpha Lipoic Acid will be administered as two 300 mg capsules taken once daily CoQ-10 will be administered as two 200mg capsules daily.
Nutritional Supplements GroupAlpha Lipoic Acid 300mgAlpha Lipoic Acid will be administered as two 300 mg capsules taken once daily CoQ-10 will be administered as two 200mg capsules daily.
Primary Outcome Measures
NameTimeMethod
Slow Harmonic AccelerationBaseline to 12 months

Change in vestibular function using the slow harmonic acceleration rotating chair test to measure change, phase and time constant. The sinusoidal harmonic acceleration (SHA) test is a diagnostic procedure used to evaluate the vestibular system, which is responsible for maintaining balance. In the sinusoidal harmonic acceleration test, a person sits in a rotational chair that moves smoothly in controlled, rhythmic oscillations. These movements stimulate the vestibular system and induce eye movements that reflect dynamic vestibular function. Abnormal findings on the SHA test may suggest unilateral or bilateral vestibular dysfunction and provide insights into the status of central compensation for vestibular issues.

Secondary Outcome Measures
NameTimeMethod
Tolerance of supplementsBaseline to 12 months

Number of adverse events experienced

Step Velocity TestBaseline to 12 months

Step velocity test involves sudden chair rotations and abrupt stops in both directions, which generate compensatory eye movements predominantly in response to the stimulated side. Abnormal findings during this test can suggest problems with the vestibular system, providing additional information about the affected side.

Number of fallsBaseline to 12 months

A count of number of falls experienced

Trial Locations

Locations (1)

University of Texas Health Science Center at San Antonio

🇺🇸

San Antonio, Texas, United States

University of Texas Health Science Center at San Antonio
🇺🇸San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath